CX3CL1 attenuates neurological deficit and neuroinflammation through CX3CR1/p38 MAPK/ERK1/2 signaling pathway in traumatic brain injury
The CX3CL1/CX3CR1 axis alleviates neuroinflammation and neurological deficits post-TBI by modulating microglial polarization via the MAPK pathway, highlighting its therapeutic potential.
Authors
- Yumei Cao (ORCID: https://orcid.org/0000-0002-0914-4145)
- Hao Zhu (ORCID: https://orcid.org/0000-0003-4138-5624)
- Yuqian Zhou (ORCID: https://orcid.org/0000-0002-8168-3952)
- Ningbo Xu (ORCID: https://orcid.org/0000-0001-9055-3597)
- Feng Xu (ORCID: https://orcid.org/0000-0002-1496-9141)
- Jianfeng Ji (ORCID: https://orcid.org/0000-0002-7933-8228)
- Xionghui Chen (ORCID: https://orcid.org/0000-0002-4866-0951)
- Peng Yang (ORCID: https://orcid.org/0000-0003-2967-4108)
Institutions
- Nantong University (CN)
- Soochow University (CN)
- Second People's Hospital of NanTong (CN)
- Zhujiang Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1016/j.intimp.2025.115765
- Citations
- 4
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.37